Blueprint Medicines Profit Margin

Blueprint Medicines (BPMC) currently reports a profit margin of -27.7% as of March 2025. That compares with -102.15% in the prior-year period — up 72.9% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Blueprint Medicines's profit margin history and peer comparisons.

Blueprint Medicines's profit margin increased from -102.15% to -27.7% — a 72.9% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Blueprint Medicines's profit margin of -27.7% is lower than the Healthcare sector average of 21.34%. That is roughly 229.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Blueprint Medicines's current -27.7% should be judged against Healthcare norms (sector average: 21.34%) and against BPMC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -27.7%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Blueprint Medicines, and consider following BPMC for alerts when major investors trade the stock.